Completed PHASE1 INTERVENTIONAL 2-arm NCT01608243

Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts

Investigation of the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma

Sponsor: Stallergenes Greer

Conditions Asthma House Dust Mite Allergy

Interventions Matching placebo SLIT tablets of house dust mite allergen extracts

Updated 6 times since 2017 Last updated: Jun 30, 2014 Started: May 31, 2012 Primary completion: Jun 30, 2014 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Asthma and House Dust Mite Allergy and is currently completed. Stallergenes Greer leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Aug 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Aug 2017 [monthly]

Completed PHASE1

First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stallergenes Greer

Data source: Stallergenes Greer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montpellier, France